請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5880
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 廖泰慶(Tai-Ching Liao) | |
dc.contributor.author | Chun-Yu Lin | en |
dc.contributor.author | 林均豫 | zh_TW |
dc.date.accessioned | 2021-05-16T16:18:00Z | - |
dc.date.available | 2018-09-01 | |
dc.date.available | 2021-05-16T16:18:00Z | - |
dc.date.copyright | 2013-08-28 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-16 | |
dc.identifier.citation | References
Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG. Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer 2012;106:199-205. Baeten D, Boots AMH, Steenbakkers PGA, Elewaut D, Bos E, Verheijden GFM, Verbruggen G, Miltenburg AMM, Rijnders AWM, Veys EM, De Keyser F. Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium. Arthritis Rheum 2000;43(6):1233-1243. Benjamin SA, Lee AC, Saunders WJ. Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in Beagles. Vet Pathol 1999;36:423-436. Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian Chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006;281(30):21082-21095. Boots AMH, Hubers H, Kouwijzer M, den Hoed-van Zandbrink L, Westrek-Esselink BM, van Doorn C, Stenger R, Bos ES, van Lierop MC, Verheijden GF, Timmers CM, van Staveren CJ. Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation. Arthritis Res Ther 2007;9(4):R71. Boussac M, Garin J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 2000;21:665-672. Chang CY, Chiou PP, Chen WJ, Li YH, Yiu JC, Cheng YH, Chen SD, Lin CT, Lai YS. Assessment of the tumorigenesis and drug susceptibility of three new canine mammary tumor cell lines. Res Vet Sci 2010;88:285-293. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002;95:267-274. Coffman FD. Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit Rev Clin Lab Sci 2008;45:531-562. Connor JR, Dodds RA, Emery JG, Kirkpatrick RB, Rosenberg M, Gowen M. Human cartilage glycoprotein 39 (HC gp-39) mRNA expression in adult and fetal chondrocytes, osteoblasts and osteocytes by in-situ hybridization. Osteoarthritis Cartilage 2000;8:87-95. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001a;285:926-931. De Ceuninck, Pastoureau P, Bouet F, Bonnet J, Vanhoutte PM. Purification of guinea pig YKL-40 and modulation of its secretion by cultured articular chondrocytes. J Cell Biochem 1998;69:414-424. Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 2011;10(5):742-751. Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, Yan W, Bentley B, Shao R. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 2011;286(17):15332-15343. Goldschmidt M, Pena L, Rasotto R, Zappulli V. Classification and grading of canine mammary tumors. Vet Pathol 2011;48(1):117-131. Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268(34):25803-25810. Harvey S, Weisman M, O’Dell J, Scott T, Krusemeier M, Visor J, Swindlehurst C. Chondrex: new marker of joint disease. Clin Chem 1998;44:509-516. Hellmen E, Moller M, Blankenstein MA, Andersson L, Westermark B. Expression of different pheynotypes in cell lines from canine mammary spindle-cell tumours and osteosarcomas indicating a pluripotent mammary stem cell origin. Breast Cancer Res Treat 2000;61:197-210. Henrissat B, Davies G. Structural and sequence-based classification of glycoside hydrolases. Curr Opin Struct Biol 1997;7:637-644. Hogdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E, Hogdall CK. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 2003;10:1535-1538. Hollak CEM, van Weely S, van Oders MHJ, Aerts JMFG. Marked elevation of plasma chitotriosidase activity. J Clin Invest 1994;93:1288-1292. Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol 2010;3(3):226-237. Houston DR, Recklies AD, Krupa JC, Van Aalten DMF. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J Biol Chem 2003;278(32):30206-30212. Hu B, Trinh K, Figueira WF, Price PA. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the Chitinase protein family. J Biol Chem 1996;271(32):19415-19420. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003;9:4423-4434. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7(5):501-512. Johansen JS, Moller S, Price PA, Bendtsen F, Junge J, Garbarsch C, Henriksen JH. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997;32:582-590. Johansen JS, CHristoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911-920. Johansen JS, Olee T, Price PA, Hashimoto S, Ochs RL, Lotz M. Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 2001;44:826-837. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172-209. Johansen JS, Olee T, Price PA, Hashimoto S, Ochs RL, Lotz M. Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 2011;44(4):826-837. Junker N, Johansen JS, Andersen CB, Kristjansen PEG. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005;48:223-231. Kawada M, Seno H, Kanda K, Nakanishi Y, Akitake R, Komekado H, Kawada K, Sakai Y, Mizoguchi E, Chiba T. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 2011;31(26):3111-3123. Krause SW, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis JD, Andreesen R. Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 1996;60(4):540-545. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 1982;389:38-48. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ. A pubic database for gene expression in human cancers. Cancer Res 1999;59:5403-5407. Lee JL, Chang CJ, Chueh LL, Lin CT. Expression of secreted frizzled-related protein 2 in a primary canine mammary tumor cell line: a candidate tumor marker for mammary tumor cells. In Vitro Cell Dev Biol Anim 2003;39:221-227. Lindahl U, Kusche-Gullberg M, Kjellen L. Regulated diversity of heparan sulfate. J Biol Chem 1998;273:24979-24982. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJT. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168-173. Markert JM, Fuller Cm, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapstone TB, Benos DJ. Differential gene expression profiling in humna brain tumors. Physiol Genomics 2001;5:21-33. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990;9(2):125-136. Millis AJT, Hoyle M, Reich E, Mann DM. Isolation and characterization of a Mr=38,000 protein from differentiating smooth muscle cells. J Biol Chem 1985;260:3754-3761. Millis AJT, Hoyle M, Kent L. In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol 1986;127:366-372. Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol 2009;20:71-77. Mohanty AK, Singh G, Paramasivam M, Saravanan K, Jabeen T, Sharma S, Yadav S, Kaur P, Kumar P, Srinivasan A, Singh TP. Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution. J Biol Chem 2003;278:14451-14460. Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417-3426. Nielsen AR, Plomgaard P, Krabbe KS, Johansen JS, Pedersen BK. IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine 2011;55:152-155. Nishikawa KC, Millis AJT. Gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003;287:79-87. Nyirkos P, Golds EE. Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem J 1990;268:265-268. Patil NS, Hall FC, Drover S, Spurrell DR, Bos E, Cope AP, Sonderstrup G, Mellins ED. Autoantigenic HCgp39 epitopes are presented by the HLA-DM-dependent presentation pathway in human B cells. J Immunol 2001;166(1):33-41. Perrimon N, Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 2000;404:725-728. Qureshi AM, Hannigan A, Campbel D, Nixon C, Wilson JB. Chitinase-like proteins are auroantigens in a model of inflammation-promoted incipient neoplasia. Genes Cancer 2011;2(1):74-87. Recklies AD, White C, Ling H. The Chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signaling pathways. Biochem J 2002;365:119-126 Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997;43:221-225. Rejman JJ, Hurley WL. Isolation and characterization of a novel 39 kilodalton whey protein from bovine mammary secretions collected during the nonlactating period. Biochem Biophys Res Commun 1988;150:329-334. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JMFG. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998;251:504-509. Schimpl M, Rush CL, Betou M, Eggleston IM, Recklies AD, Van Aalten DMF. Human YKL-39 is a pseudo-chitinase with retained chitooligosaccharide-binding properties. Biochem J 2012;446:149-157. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006;106:1130-1139. Scully S, Yan W, Bentley B, Cao QJ, Shao R. Inhibitory activity of YKL-40 in mammary epithelial cell differentiation and polarization induced by lactogenic hormones: a role in mammary tissue involution. PLoS One 2011;6(10):e25819. Shackelton LM, Mann DM, Millis AJT. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995;270:13076-13083. Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer 2011;105:1203-1209. Shao R, Hamel K, Peterson L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009;28:4456-4468. Steenbakkers PGA, Baeten D, Rovers E, Veys EM, Rijnders AWM, Meijerink J, De Keyser F, Boots AMH. Localization of MHC class II/human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies. J Immunol 2003;170:5719-5727. Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, Calafat J, Borregaard N. YKL-40, a mammalian member of the Chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998;110:351-360. Vos K, Miltenburg AMM, van Meijgaarden KE, van den Heuvel M, Elferink DG, van Galen PJM, van Hogezand RA, van Vliet-Daskalopoulou E, Ottenhoff THM, Breedveld FC, Boots AMH, de Vries RRP. Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions. Rheumatology 2000;39(12):1326-1331. Watanabe T, Kobori K, Miyashita K, Fujii T, Sakai H, Uchida M, Tanada H. Identification of glutamic acid 204 and aspartic acid 200 in Chitinase A1 of Bacillus circulans WL-12 as essential residues for Chitinase activity. J Biol Chem 1993;268:18567-18572. Watanabe T, Uchida M, Kobori K, Tanaka H. Site-directed mutagenesis of the Asp-197 and Asp-202 residues in Chitinase A1 of Bacillus circulans WL-12. Biosci Biotechnol Biochem 1994;58:2283-2285. Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 2008;25:801-809. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5880 | - |
dc.description.abstract | YKL-40 首次被發現於人類的骨瘤細胞株MG63中,為一分泌型之醣蛋白。其命名來自其蛋白胺基酸序列N端之前三個胺基酸,分別是酪胺酸(Y)、賴胺酸(K)以及白胺酸(L),取其縮寫並加上其分子重量約為40 kDa,因此命名為YKL-40。此外由於YKL-40具有類似幾丁酶可結合幾丁質之能力而有別名CHI3L1(chitinase-3-like-1),但其主要作用區域之胺基酸由白胺酸(leucine)所取代,因而失去幾丁酶之活性。過往關於YKL-40的研究皆以人類疾病及實驗動物為主,與犬隻相關的研究發表屈指可數。而在YKL-40與癌症相關的研究中,一般認為血清中增量之YKL-40與許多種類之癌症及預後不良有關。近期的研究也指出YKL-40具有調控血管新生的能力。然而YKL-40確切的功用與作用機制仍尚未明瞭,更遑論犬隻YKL-40的研究仍屬稀少。本研究將以BALB/3T3細胞進行轉染帶有犬隻YKL-40基因的載體,透過真核系統之細胞株穩定表現此分泌型醣蛋白。合成後的蛋白會被分泌至培養液中,收集後經濃縮後進行純化。之後利用犬隻乳腺癌細胞株CMT-1及MPG來進行YKL-40生物功能的測試與評估,包括:細胞增生試驗、細胞移行試驗以及細胞侵入能力試驗等。在最低100 ng/mL的濃度下,YKL-40對於促進細胞移行及侵入具有一定的效果,然而在細胞增生的能力並不顯著。而在細胞訊息傳遞路徑的探索上,發現YKL-40具有活化AKT的能力,推測其主要透過此一路徑進行訊息傳遞。 | zh_TW |
dc.description.abstract | YKL-40 was first identified as a secretory glycoprotein from a human osteosarcoma cell line, MG63. This protein is named based on its molecular weight of 40 kDa and N-terminal amino acids tyrosine (Y), lysine (K), and leucine (L). It is also known as CHI3L1 (chitinase-3-like-1), which has the chitin-binding affinity but lacks the chitinase activity due to the substitution of an essential glutamic acid with leucine in the chitinase-3-like catalytic domain. During the past decade, most of YKL-40 studies were focused on human diseases and experimental animal models such as mice, and little information of canine research was presented so far. Elevated serum YKL-40 has been associated with worse prognosis in a variety of human cancers. Recent studies suggested that YKL-40 plays a role in regulation of tumor angiogenesis. However, the real function and molecular mechanism of YKL-40 still remained unknown, and the investigation on canine source YKL-40 protein was also rare. We have reported previously the molecular cloning of the canine YKL-40 gene and a predicted YKL-40 protein structure. In this study, a transfection was performed on BALB/3T3 cell to establish a stable cell line which can overexpress canine YKL-40 protein. Recombinant canine YKL-40 protein was then concentrated and purified from the cultured medium of the transfected cell line. The biological functions of this protein were evaluated on the canine mammary gland tumor (MGT) cells including proliferation, migration and invasion assays, etc.. YKL-40 at a concentration as low as 100 ng/mL seem to has effect in cell migration and invasion, yet little effect in cell proliferation. The alterations of molecular signaling induced by addition of YKL-40 protein will be also evaluated on canine MGT cells. | en |
dc.description.provenance | Made available in DSpace on 2021-05-16T16:18:00Z (GMT). No. of bitstreams: 1 ntu-102-R00629012-1.pdf: 2019717 bytes, checksum: 680362a9bfa8699a4ff30f32f57b5775 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | Contents
中文摘要 I Abstract II Chapter 1 Background and Literatures Review 1 1.1 YKL-40 1 1.1.1 Expression and regulation of YKL-40 2 1.1.2 Biological properties of YKL-40 6 1.1.3 YKL-40 in infectious, chronic inflammation and joint diseases 9 1.1.4 YKL-40 in cancer diseases 10 1.1.5 YKL-40 may be an autoantigen 11 1.1.6 YKL-40 in cell migration 12 1.1.7 Possible cell signal pathway of YKL-40 13 1.2 Canine mammary gland tumor 13 1.3 Conclusion 14 Chapter 2 Introduction 16 Chapter 3 Material and Method 19 3.1 Experimental animals 19 3.2 Cell lines 19 3.3 Anitbodies 20 3.4 Total RNA extraction 20 3.5 RT-PCR 21 3.6 Preparation and propagation of YKL-40/pcDNA 3.1 plasmid 22 3.7 Transfection of canine YKL-40 gene into BALB/3T3 cells 22 3.8 Expression of canine YKL-40 protein in BALB/3T3 cells 23 3.9 Concentration of the recombinant canine YKL-40 protein 23 3.10 Purification of the recombinant canine YKL-40 protein 24 3.11 Quantification of the recombinant canine YKL-40 protein 24 3.12 Identification of the purified recombinant canine YKL-40 protein 25 3.13 Western blot analysis 25 3.14 Proliferation assay 26 3.15 Migration assay 26 3.16 Invasion assay 27 3.17 Autoantigen analysis 27 3.18 Cell signal pathway analysis 28 Chapter 4 Results 30 4.1 YKL-40 protein expression by stable cell line establishment 30 4.2 YKL-40 mRNA expression examination 30 4.3 Purification of the recombinant canine YKL-40 31 4.4 Proliferation assay 32 4.5 Migration assay 32 4.6 Invasion assay 33 4.7 Cell signal pathway analysis 33 Chapter 5 Discussion 35 Tables 40 Table 1. Reverse transcription protocol 40 Table 2. YKL-40 primer list 41 Figures 42 Figure 1. The construct of canine YKL-40/pcDNA 3.1/V5-HIS-TOPO. 42 Figure 2. Expression of the YKL-40 mRNA in different tumor cell lines. 43 Figure 3. The transfection of YKL-40 into BALB/3T3 cells 44 Figure 4. Purification of the recombinant YKL-40 protein with His-column and Heparin-column 45 Figure 5. YKL-40 increases the proliferation rate of CMT-1 and MPG cells. 46 Figure 6. The result of cell migration assay on CMT-1 cells 47 Figure 7. The result of cell migration assay on MPG cells 48 Figure 8. YKL-40 stimulates the invasion ability of CMT-1 cells. 50 Figure 9. YKL-40 stimulates the invasion ability of CMT-1 cells. 52 Figure 10. Autoantigenicity of YKL-40 53 Figure 11. The PI3K/AKT and MAPK pathway analysis on CMT-1 and MPG cells 54 References 55 | |
dc.language.iso | en | |
dc.title | 犬YKL-40重組蛋白之表現及其在犬乳腺腫瘤細胞之作用 | zh_TW |
dc.title | Recombinant Canine YKL-40 Expression and Its Effects on Canine Mammary Gland Tumor Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 施能耀(Neng-Yao Shih),郭村勇(Tsun-Yung Kuo),王愈善(Yu-Shan Wang),林辰栖 | |
dc.subject.keyword | YKL-40,CHI3L1,犬乳腺腫瘤, | zh_TW |
dc.subject.keyword | YKL-40,CHI3L1,canine mammary gland tumor, | en |
dc.relation.page | 65 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2013-08-16 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
顯示於系所單位: | 獸醫學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf | 1.97 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。